Document is current

Article History

Received: 4 December 2024

Accepted: 4 January 2025

First Online: 31 January 2025

Declarations

:

: MG reports consultancy and honoraria from Amgen, AOP Pharma, Novartis, BMS, AbbVie, Pfizer, Roche, Janssen, Gilead, AstraZeneca, Sierra, Lilly, GSK. JNE received research funding from Novartis; advisory boards or consulting fees from AstraZeneca, Johnson&Johnson, and Novartis; received honoraria from Amgen, AstraZeneca, Novartis, and Pfizer; received travel support from AstraZeneca, Johnson&Johnson, and Merck; is a co-owner of Cancilico; had a patent issued for artificial intelligence-based image classification software. SK received research funding from Geron, Janssen, AOP Pharma, and Novartis; received advisory board or consulting fees from Pfizer, Incyte, Ariad, Novartis, AOP Pharma, Bristol Myers Squibb, Celgene, Geron, Janssen, CTI BioPharma, Roche, Bayer, GSK, Sierra Oncology, PharmaEssentia, and MSD; received payment or honoraria from Novartis, BMS/Celgene, Pfizer; received travel/accommodation support from Alexion, Novartis, Bristol Myers Squibb, Incyte, AOP Pharma, CTI BioPharma, Pfizer, Celgene, Janssen, Geron, Roche, AbbVie, GSK, Sierra Oncology, Kartos, and MSD; had a patent issued for a BET inhibitor at RWTH Aachen University. BS received advisory board or consulting fees from AbbVie, AOP Pharma, AstraZeneca, BeiGene, Bristol Myers Squibb, Hexal, Incyte, Janssen-Cilag, Novartis, Oncopeptides, Pfizer, Sanofi and SoBi. FHH served as an advisor for Novartis, CTI, Celgene/BMS, Janssen, Abbvie, GSK, Merck and AOP and received research funding from Novartis, Celgene/BMS and CTI.